A cost-effectiveness evaluation of a jail-based chlamydia screening program for men and its impact on their partners in the community

Sexually Transmitted Diseases

Volumn 33, Issue 10 SUPPL., 2006, Pages

  Gift, Thomas L ^a   Lincoln, Thomas ^b,c,d   Tuthill, Robert ^e   Whelan, Michael ^f   Briggs, L Patricia ^f   Conklin, Thomas ^b   Irwin, Kathleen L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b BAYSTATE MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Hampden County Correctional Center   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

^f MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHLAMYDIA; CHLAMYDIASIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; GONORRHEA; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRISON; SCREENING; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; CHLAMYDIA INFECTIONS; CONTACT TRACING; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MASS SCREENING; MASSACHUSETTS; PRISONERS;

EID: 33748988722     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000235169.45680.7c     Document Type: Article

References (50)

1. Conklin TJ, Lincoln T, Tuthill RW. Self-reported health and prior health behaviors of newly admitted correctional inmates. Am J Public Health 2000; 90:1939-1941.
2. National Commission on Correctional Health Care. The Health Status of Soon-to-Be-Released Inmates: A Report to Congress, vol I, 6-1-2002. Chicago, National Commission on Correctional Health Care, 2002:1-105.
3. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2002. Atlanta: US Department of Health and Human Services, Public Health Service, 2003:1-150.
4. Centers for Disease Control and Prevention. Assessment of sexually transmitted diseases services in city and county jails - United States, 1997. MMWR Morb Mortal Wkly Rep 1998; 47:429-431.
5. Jolly AM, Wylie JL. Gonorrhoea and chlamydia core groups and sexual networks in Manitoba. Sex Transm Infect 2002; 78(suppl 1):i145-i151.
6. Rothenberg RB, Potterat JJ, Woodhouse DE. Personal risk taking and the spread of disease: Beyond core groups. J Infect Dis 1996; 174(suppl 2):S144-S149.
7. Hammett TM. Public Health/Corrections Collaborations: Prevention and Treatment of HIV/AIDS, STDs and TB. NCJ 169590. Washington, DC: US Department of Justice, National Institute of Justice, 1998:1-19.
8. Golden MR, Hogben M, Handsfield HH, St. Lawrence JS, Potterat JJ, Holmes KK. Partner notification: Low coverage for gonorrhea, chlamydia, and HIV. Sex Transm Dis 2003; 30:490-496.
9. Kraut-Becher JR, Gift TL, Haddix AC, Irwin KL, Greifinger RB. Cost-effectiveness of universal screening for chlamydia and gonorrhea in US jails. J Urban Health 2004; 81:453-471.
10. US Preventive Services Task Force. Screening for chlamydial infection - Including ocular prophylaxis in newborns. In: Guide to Clinical Preventive Services. McLean, VA: International Medical Publishing, 2002:325-333.
11. Stamm W, Holmes KK. Chlamydia trachomatis infections of the adult. In: Holmes KK, Sparling PF, Mardh P-A, et al., eds. Sexually Transmitted Diseases. New York: McGraw-Hill, 1999:407-422.
12. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: Implications for prevention of sexual transmission of HIV-1. Lancet 1997; 349:1868-1873.
13. Oh MK, Smith KR, O'Cain M, Kilmer D, Johnson J, Hook EW III. Urine-based screening of adolescents in detention to guide treatment for gonococcal and chlamydial infections. Arch Ped Adolesc Med 1998; 152:52-56.
14. Mertz KJ, Voigt RA, Hutchins K, Levine WC, The Jail STD Prevalence Monitoring Group. Findings from STD screening of adolescents and adults entering corrections facilities. Sex Transm Dis 2002; 29:834-839.
15. Risser JMH, Risser WL, Gefter LR, Brandstetter DM, Cromwell PF. Implementation of a screening program for chlamydial infection in incarcerated adolescents. Sex Transm Dis 2001; 28:43-46.
16. Conklin TJ, Lincoln T, Flanigan TP. A public health model to connect correctional health care with communities. Am J Public Health 1998; 88:1249-1250.
17. Quinn TC, Gaydos CA, Shepherd M, et al. Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships. JAMA 1996; 276:1737-1742.
18. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20(suppl 1):S47-S65.
19. 2001 Sexually Transmitted Disease Laboratory Test Method Survey. Washington, DC: Association of Public Health Laboratories, 2002:1-19.
20. Howell MR, Quinn TC, Brathwaite W, Gaydos CA. Screening women for Chlamydia trachomatis in family planning clinics. Sex Transm Dis 1998; 25:108-117.
21. 2001 Drug Topics Red Book. Montvale, NJ: Medical Economics Co, Inc, 2001.
22. Begley CE, McGill L, Smith PB. The incremental cost of screening, diagnosis, and treatment of gonorrhea and chlamydia in a family planning clinic. Sex Transm Dis 1989; 16:63-67.
23. Gift TL, Owens CJ. The direct medical cost of epididymitis and orchitis: Evidence from an analysis of insurance claims. Sex Transm Dis 2006; 33(10) supplement:S84-S88.
24. Chlamydia. In: Stratton KR, Durch JS, Lawrence RS, eds. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC, 1999:149-158.
25. Rein D, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: Decreasing, but still substantial. Obstet Gynecol 2000; 95:397-402.
26. Shafer M-AB, Pantell RH, Schachter J. Is the routine pelvic examination needed with the advent of urine-based screening for sexually transmitted diseases? Arch Pediatr Adolesc Med 1999; 153:119-125.
27. Yeh JM, Hook EW III, Goldie SJ. A refined estimate of the average lifetime cost of pelvic inflammatory disease. Sex Transm Dis 2003; 30:369-378.
28. Bureau of Labor Statistics. Consumer price index - all urban consumers; 2003 [cited Dec 1, 2003]. Available at: http://www.bls.gov/cpihome.htm.
29. Douglas JM Jr, Newman D, Bolan G, et al. Low rate of pelvic inflammatory disease (PID) among women with incident Chlamydia trachomatis (CT) infection [Abstract]. Int J STD AIDS 2001; 12(suppl 2):65.
30. Washington AE, Johnson RE, Sanders LL Jr. Chlamydia trachomatis infections in the United States: What are they costing us? JAMA 1987; 257:2070-2072.
31. Wiesenfeld HC, Hillier SL, Krohn MA, et al. Lower genital tract infection and endometritis: Insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002; 100:456-463.
32. Magid D, Douglas JM Jr, Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: An incremental cost-effectiveness analysis. Ann Intern Med 1996; 124:389-399.
33. Johnson RE, Green TA, Schachter J, et al. Evaluation of nucleic acid amplification tests as reference tests for Chlamydia trachomatis infections in asymptomatic men. J Clin Microbiol 2000; 38:4382-4386.
34. Koumans EH, Johnson RE, Knapp JS, St. Louis ME. Laboratory testing for Neisseria gonorrhoeae by recently introduced nonculture tests: A performance review with clinical and public health considerations. Clin Infect Dis 1999; 27:1171-1180.
35. Martin DH, Mroczkowski TF, Dalu ZA, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N Engl J Med 1992; 327:921-925.
36. Hillis SD, Coles FB, Litchfield B, et al. Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. Sex Transm Dis 1998; 25:5-11.
37. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep MMWR 2002; 51(RR-6):1-80.
38. Rice RJ, Knapp JS. Antimicrobial susceptibilities of Neisseria gonorrhoeae strains representing five distinct resistance phenotypes. Antimicrob Agents Chemother 1994; 38:155-158.
39. Waugh M. Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women. J Antimicrob Chemother 1993; 31(suppl E):193-198.
40. Ratelle S, Nguyen MS, Tang Y, Whelan M, Etkind P, Lincoln T, Dumas W. Low sensitivity of the leukocyte esterase test (LET) in detecting Chlamydia trachomatis infections in asymptomatic men entering a county jail. J Correctional Health Care 2004; 10:217-226.
41. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2001. Atlanta: US Department of Health and Human Services, Public Health Service, 2002:1-133.
42. Hook EW III, Handsfield HH. Gonococcal infections in the adult. In: Holmes KK, Sparling PF, Mardh P-A, et al., eds. Sexually Transmitted Diseases. New York: McGraw-Hill, 1999:451-466.
43. Haddix AC, Hillis SD, Kassler WJ. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis 1995; 22:274-280.
44. Crotchfelt KA, Pare B, Gaydos C, Quinn TC. Detection of Chlamydia trachomatis by the Gen-Probe AMPLIFIED Chlamydia trachomatis assay (AMP CT) in urine specimens from men and women and endocervical specimens from women. J Clin Microbiol 1998; 36:391-394.
45. Fox KK, Knapp JS, Holmes KK, et al. Antimicrobial resistance in Neisseria gonorrhoeae in the United States, 1988-1994: The emergence of decreased susceptibility to the fluoroquinolones. J Infect Dis 1997; 175:1396-1403.
46. Welte R, Kretzschmar M, Leidl R, Van Den Hoek A, Jager JC, Postma MJ. Cost-effectiveness of screening programs for Chlamydia trachomatis. Sex Transm Dis 2000; 27:518-529.
47. Nguyen MS, Ratelle S, Tang Y, et al. Prevalence and indicators of Chlamydia trachomatis infections among men entering Massachusetts correctional facilities: Policy implications. J Correctional Health Care 2004; 10:543-554.
48. Mrus JM, Biro FM, Huang B, Tsevat J. Evaluating adolescents in juvenile detention facilities for urogenital chlamydial infection. Arch Pediatr Adolesc Med 2003; 157:696-702.
49. Black CM. Current methods of laboratory diagnosis of Chlamydia trachomatis infections. Clin Microbiol Rev 1997; 10:160-184.
50. Chesson HW, Pinkerton SD. Sexually transmitted diseases and the increased risk for HIV transmission: Implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions. J Acquir Immun Defic Syndr 2000; 24:48-56.